Logo Image
News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2026|
Sales Effectiveness
Advertisement

Namita Powers

Advertisement

Principal, ZS (Philadelphia)

Articles by Namita Powers

Why Pharma Must Invest in Key Account Management Capabilities

ByNamita Powers,Mike Moorman,Alex Simon
July 20th 2021

The emergence of organized customers demands investment in advanced solutions and next-generation key account management.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on PharmExec

    1

    EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval

    2

    Reading Between the Lines: Closing the T1D Misdiagnosis Gap

    3

    Pharmaceutical Executive Daily: FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer

    4

    Novartis Announces $105 Million Collaborative Agreement with Antares Therapeutics

    5

    The Rise of Direct-to-Patient Models in Pharma: Opportunities and Risks in Bypassing Traditional Distribution Channels

    • About
    • Advertise
    • Contact Us
    • Editorial Board
    • Editorial Submission Guidelines
    • Do Not Sell My Personal Information
    • Privacy Policy
    • Terms and Conditions
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    Brand Logo

    © 2026 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us